A Stromal Lysolipid-Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression.


Journal

Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693

Informations de publication

Date de publication:
05 2019
Historique:
received: 12 10 2018
revised: 03 02 2019
accepted: 28 02 2019
pubmed: 7 3 2019
medline: 2 6 2020
entrez: 7 3 2019
Statut: ppublish

Résumé

Pancreatic ductal adenocarcinoma (PDAC) develops a pronounced stromal response reflecting an aberrant wound-healing process. This stromal reaction features transdifferentiation of tissue-resident pancreatic stellate cells (PSC) into activated cancer-associated fibroblasts, a process induced by PDAC cells but of unclear significance for PDAC progression. Here, we show that PSCs undergo a dramatic lipid metabolic shift during differentiation in the context of pancreatic tumorigenesis, including remodeling of the intracellular lipidome and secretion of abundant lipids in the activated, fibroblastic state. Specifically, stroma-derived lysophosphatidylcholines support PDAC cell synthesis of phosphatidylcholines, key components of cell membranes, and also facilitate production of the potent wound-healing mediator lysophosphatidic acid (LPA) by the extracellular enzyme autotaxin, which is overexpressed in PDAC. The autotaxin-LPA axis promotes PDAC cell proliferation, migration, and AKT activation, and genetic or pharmacologic autotaxin inhibition suppresses PDAC growth

Identifiants

pubmed: 30837243
pii: 2159-8290.CD-18-1212
doi: 10.1158/2159-8290.CD-18-1212
pmc: PMC6497553
mid: NIHMS1523395
doi:

Substances chimiques

Lysophosphatidylcholines 0
Phosphoric Diester Hydrolases EC 3.1.4.-
alkylglycerophosphoethanolamine phosphodiesterase EC 3.1.4.39

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

617-627

Subventions

Organisme : Cancer Research UK
ID : C50242/A17728
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R00 CA188259
Pays : United States
Organisme : NCI NIH HHS
ID : K99 CA188259
Pays : United States
Organisme : Cancer Research UK
ID : C596/A18076
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA186241
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA196228
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA229580
Pays : United States
Organisme : Cancer Research UK
ID : C596/A17196
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P01058X/1
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P30 CA014195
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

©2019 American Association for Cancer Research.

Références

Science. 2009 Jun 12;324(5933):1457-61
pubmed: 19460966
J Exp Med. 2017 Mar 6;214(3):579-596
pubmed: 28232471
J Lipid Res. 2014 Aug;55(8):1784-96
pubmed: 24872406
Gastroenterology. 2015 Jul;149(1):201-10
pubmed: 25888329
Nat Rev Cancer. 2003 Aug;3(8):582-91
pubmed: 12894246
Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):E3091-100
pubmed: 25024225
Annu Rev Pharmacol Toxicol. 2010;50:157-86
pubmed: 20055701
Cell. 2016 May 5;165(4):910-20
pubmed: 27087446
Cancer Immunol Res. 2015 Apr;3(4):399-411
pubmed: 25678581
Nat Med. 2017 Feb;23(2):235-241
pubmed: 28024083
Nature. 2016 Aug 25;536(7617):479-83
pubmed: 27509858
Cancer Cell. 2014 Jun 16;25(6):719-34
pubmed: 24856586
Cancer Cell. 2014 Jun 16;25(6):735-47
pubmed: 24856585
Cancer Res. 2008 Feb 1;68(3):918-26
pubmed: 18245495
Annu Rev Cell Dev Biol. 2018 Oct 6;34:333-355
pubmed: 30028641
Cancer Discov. 2018 Aug;8(8):1006-1025
pubmed: 29903879
Gastroenterology. 1998 Aug;115(2):421-32
pubmed: 9679048
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Cancer Cell. 2012 Mar 20;21(3):418-29
pubmed: 22439937
Trends Endocrinol Metab. 2016 Oct;27(10):696-705
pubmed: 27365163
Dev Cell. 2015 Mar 23;32(6):678-92
pubmed: 25752962
Nature. 2013 May 30;497(7451):633-7
pubmed: 23665962
Cancer Discov. 2012 Aug;2(8):685-93
pubmed: 22628411
Cell. 2014 Sep 25;159(1):80-93
pubmed: 25259922
Gastroenterology. 2013 Jun;144(6):1210-9
pubmed: 23622130
Gut. 2015 Sep;64(9):1476-84
pubmed: 25994217
Elife. 2016 Feb 27;5:e10250
pubmed: 26920219
PLoS One. 2017 Dec 6;12(12):e0189051
pubmed: 29211796
Gut. 2013 Jan;62(1):112-20
pubmed: 22466618
PLoS One. 2014 Apr 18;9(4):e93230
pubmed: 24747415
Proc Natl Acad Sci U S A. 2013 May 28;110(22):8882-7
pubmed: 23671091
Cancer Res. 2015 Feb 1;75(3):544-53
pubmed: 25644265

Auteurs

Francesca R Auciello (FR)

Cancer Research UK Beatson Institute, Glasgow, UK.
Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.

Vinay Bulusu (V)

Cancer Research UK Beatson Institute, Glasgow, UK.
Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.

Chet Oon (C)

Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon.

Jacqueline Tait-Mulder (J)

Cancer Research UK Beatson Institute, Glasgow, UK.
Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.

Mark Berry (M)

Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon.

Sohinee Bhattacharyya (S)

Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon.

Sergey Tumanov (S)

Cancer Research UK Beatson Institute, Glasgow, UK.
Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.

Brittany L Allen-Petersen (BL)

Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon.

Jason Link (J)

Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon.

Nicholas D Kendsersky (ND)

Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon.

Esmee Vringer (E)

Cancer Research UK Beatson Institute, Glasgow, UK.
Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.

Michelle Schug (M)

Cancer Research UK Beatson Institute, Glasgow, UK.
Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.

David Novo (D)

Cancer Research UK Beatson Institute, Glasgow, UK.

Rosa F Hwang (RF)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Ronald M Evans (RM)

The Salk Institute for Biological Studies, Gene Expression Laboratory, Howard Hughes Medical Institute, La Jolla, California.

Colin Nixon (C)

Cancer Research UK Beatson Institute, Glasgow, UK.

Craig Dorrell (C)

Oregon Health & Science University Brenden-Colson Center for Pancreatic Care, Portland, Oregon.

Jennifer P Morton (JP)

Cancer Research UK Beatson Institute, Glasgow, UK.

Jim C Norman (JC)

Cancer Research UK Beatson Institute, Glasgow, UK.

Rosalie C Sears (RC)

Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon.

Jurre J Kamphorst (JJ)

Cancer Research UK Beatson Institute, Glasgow, UK. shermama@ohsu.edu jurre.kamphorst@glasgow.ac.uk.
Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.

Mara H Sherman (MH)

Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon. shermama@ohsu.edu jurre.kamphorst@glasgow.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH